The Prospects For Clinical Stage Idera Pharmaceuticals Inc (NASDAQ:IDRA)
[[tagnumber 0]][[tagnumber 1]]If you have followed the stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) for the last few months, you might be disappointed with the stock‘s performance in 2015 so far. While IDRA shares could be bought and sold at $5 per share or higher in early–2015, this is no longer the case and the stock has since considerably depreciated in value. Is the company posed for a rebound any time soon, though?[[tagnumber 2]] [[tagnumber 0]]According to CEO Vincent Milano, whatever good that will supposedly happen to the company has been scheduled for the fourth quarter of 2015. This is when Milano expects to have a couple of new trials launched and the results of a few ongoing collected. Regardless of what these results will reveal, one thing is for sure – IDRA seems unlikely to start making money any time soon and this is confirmed by analysts‘ estimates. The latter project per–share losses of $0.46, $0.23 and $0.43 for the 2015, 2016 and 2017 fiscal years, respectively.[[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]While this forecast does not necessarily mean that IDRA is on the lower end of the investment spectrum, it does indicate that whatever potential the stock may have must be searched for in the long term rather than the short. This notion might be resonating with the majority of IDRA investors since the vast majority of them are shorting the stock. And while the stock may seem poised to go south in the forthcoming months, prospective shorters should bear in mind that it might take two weeks to close out a short position should they decide to open one right now.[[tagnumber 2]] [[tagnumber 0]]Idera Pharmaceuticals is a clinical–stage biotech focused on providing medical solutions for life–threatening diseases and some types of non–Hodgkin lymphoma in particular. Provided that the interim clinical results expected by the end of the year prove statistically significant and justify going to the next phase, IDRA shares could enjoy a nice rebound on the charts. In the meantime, we will keep an eye on any corporate updates in the months to come to see how well management is doing to increase the fundamental value of the company their are in charge of.[[tagnumber 2]]
